Previous 10 | Next 10 |
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE PR Newswire Company Anticipates No Impact on U.S. and European Royalty Revenues from DARZALEX FASPRO ® and SC through at least 2030 Reiterates 2023 Revenue Guidance of $815 mill...
Summary HALO has mediocre financials, questionable outlook. Absolute market share ensures demand for its products. Que Capital recommends a strong hold, until profit margins improve. Thesis Over the past year, Halozyme Therapeutics' (HALO) stock price has risen by ...
Summary Bernzott Capital Advisors are independent money managers for institutional, intermediary and private clients. Our investment philosophy is fundamentally based and time tested. Macro factors weighed heavily on stock prices all year, hurting interest sensitive sectors and aiding d...
The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Halozyme Therapeutics, Inc. 2022 Q4 - Results - Earnings Call Presentation
Halozyme Therapeutics, Inc. (HALO) Q4 2022 Earnings Conference Call February 21, 2023, 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations and Corporate Communications Dr. Helen Torley - President and CEO Nicole LaBrosse - Chief Financial Offi...
Halozyme Therapeutics press release ( NASDAQ: HALO ): Q4 Non-GAAP EPS of $0.48 beats by $0.01 . Revenue of $181.5M (+77.9% Y/Y) misses by $10.55M . Record Fourth Quarter Royalty Revenue Increased 69% YOY to $106.0 million; Record Full Year Royalty Revenue Increased 77%...
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS PR Newswire Fourth Quarter Revenue Increased 78% YOY to $181 million ; GAAP Diluted Earnings per Share of $0.42 and Non-GAAP Diluted Earnings per Share of $0.48 1 Full Ye...
Halozyme to Report Fourth Quarter and Full Year 2022 Financial and Operating Results PR Newswire SAN DIEGO , Feb. 7, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2022...
Halozyme Appoints Barbara Duncan to its Board of Directors PR Newswire SAN DIEGO , Feb. 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the appointment of Barbara Duncan to its Board of Directors. Ms. Duncan bri...
Summary Avid Bioservices is primed to more than double capacity over the next few quarters. Perception should change as Avid fills its new capacity and develops into a free cash flow machine. It would not surprise me to see fast growing, recession resistant cash flows valued at 20x,...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...